CEACAM5 and cancer: Five years later, Conry RM and colleagues extended this approach to cancer immunotherapy by delivering mRNA encoding carcinoembryonic antigen (CEA), successfully inducing antigen-specific antibodies and cytotoxic T lymphocytes (CTLs) in murine models, thus validating the feasibility of mRNA-based cancer vaccines [35].